Studio E.R. Congressi
With the unrestricted educational grant of

Friday, May 24, 2019

SESSION I: MYELODYSPLASTIC SYNDROMES

Chairman: E. Angelucci

MDS: recent advances overview
A. Giagounidis
Therapy of lower risk
R. Latagliata
Therapy of higher risk
V. Santini
Supportive therapy
P. Musto
Timing allografting
M.G. Della Porta

SESSION II: ACUTE MYELOID LEUKEMIA

Chairmen: S. Amadori, F. Ciceri

Risk stratification and MRD
N. Russell
Current management in younger adults
A. Venditti
Current management in older patients
A. Isidori
Immunotherapy: where are we now?
A. Curti
Discussion
F. Ciceri

SESSION III: ACUTE LYMPHOBLASTIC LEUKEMIA

Chairman: R. Foà

Mouse model of human ALL
G. Inghirami
Management of Ph positive patients
S. Chiaretti
Management of Ph negative patients
R. Bassan
Digital-doplet PCR for MRD monitoring
I. Della Starza
CAR-T and CIK
A. Rambaldi

SESSION IV: CHRONIC LYMPHOCYTIC LEUKEMIA

Chairman: G. Pizzolo

Stereotyped receptors
P. Baliakas
BCR and cell signaling
P. Ghia
Real life studies
M. Montillo
Guidelines: open issues
S. Molica
Prospects for future improvement
G. Pizzolo

Saturday, May 25, 2019

JOHN GOLDMAN LECTURE
M.J. Mauro

SESSION V: CHRONIC MYELOID LEUKEMIA

Chairman: G. Saglio

ELN guidelines
J. Apperley
The Italian CML registry
G. Specchia / G. Saglio
CML and pregnancy
E. Abruzzese
Treatment discontinuation for CML in clinical practice
C. Fava
New drugs and future combination therapy
M. Breccia

SESSION VI: NEW DRUGS AND NEW PERSPECTIVES IN ONCO-HEMATOLOGY

Chairman: F. Pane

Aggressive non-Hodgkin lymphomas
U. Vitolo
Hodgkin lymphoma
M. Spina
Waldenström macroglobulinemia
A. Tedeschi

SESSION VII: MYELOPROLIFERATIVE NEOPLASMS

Chairman: A.M. Vannucchi

Molecular basis
I. Plo
Integrate prognostic score
P. Guglielmelli
Present and future of JAK2 inhibitors
F. Passamonti
Stem cell transplantation in 2019
W. Arcese / R. Cerretti
A critical reappraisal of antithrombotic therapy
V. De Stefano

Studio E.R. Congressi s.r.l.
Via de' Poeti, 1
40124 Bologna BO
P.IVA 06301101009